Body composition study for liver cancer patients having TACE
Part of Cancer, Digestive system clinical trials.
This trial uses deep learning to analyze body composition from scans in people with hepatocellular carcinoma (HCC) who are undergoing TACE (a treatment that blocks blood flow to the tumor). It aims to predict outcomes better and may help doctors tailor care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hepatocellular carcinoma (liver cancer) between January 1, 2018 and May 31, 2024.
- You are older than 18 years.
- Your medical images (like CT or MRI) are clear and usable for analysis.
- You have not had follow-up lost during your care.
- You do not have any other type of cancer besides liver cancer.
- Your medical records are complete.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a computer model to predict if your liver cancer might come back aggressively after surgery. If you are at high risk, you may receive additional treatment before surgery to lower that risk.
This study is looking for blood markers that may help doctors learn how well TACE treatment is working for liver cancer. You need to be scheduled for TACE and have a follow-up scan to participate.
This study looks at blood tests to see if they can predict how well liver cancer responds to a procedure called TACE. Participation involves giving blood samples and having your normal follow-up scans.
This study uses digital scans of your tumor tissue and CT/MRI images to build a computer model that helps predict whether you might need extra treatment (adjuvant therapy) after liver cancer surgery. The goal is to use your own tissue and scan data to personalize follow-up care.
This trial tests whether measuring the liver tumor with a CT scan can help doctors plan the best treatment. It aims to improve how well the treatment works and reduce side effects.
This trial is testing a new computer tool that uses your own scans to plan TARE treatment for liver cancer. The goal is to make the treatment more personalized and effective.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.